Non-interventional study of patients with PN NF1 starting selumetinib in Russia

Study identifier:D1340R00002

ClinicalTrials.gov identifier:NCT05891847

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Non-interventional study of patients with plexiform neurofibromas and neurofibromatosis type I starting selumetinib in Russia

Medical condition

neurofibroma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

150

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 21 Mar 2023
Estimated Primary Completion Date: 20 Mar 2026
Estimated Study Completion Date: 20 Mar 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria